MUC1 Is Upregulated in Advanced Prostate Cancer and Is an Independent Prognostic Factor
MUC1 expression was evaluated in tissue microarrays constructed from 119 nodal positive prostate cancer patients treated by radical prostatectomy and extended lymphadenectomy. MUC1 status was correlated with various tumor features and biochemical recurrence-free, disease-specific survival and overall survival. [Prostate Cancer Prostatic Dis] Abstract
MRI-Guided Prostate Adaptive Radiotherapy – A Systematic Review
The authors review published studies on the influences of varies types of motion on daily prostate position and how these may be mitigated to improve image-guided radiotherapy (IGRT) in future. In particular the role that MRI has played in the generation of data is discussed and the potential role of the MR-Linac in next-generation IGRT is discussed. [Radiother Oncol] Abstract
Visit our reviews page to see a complete list of reviews in the prostate cell research field.
SCIENCE NEWS
BRCA Gene Mutations Associated with Increased Prostate Cancer Risk
Though predominantly known for their increased associations with breast cancer risk, germline mutations in the BRCA1 and BRCA2 genes are also associated with an increased susceptibility to other diseases, including prostate cancer. New data being presented highlights new research on the role that genetic sequencing and testing could play in prostate cancer screening and treatment. [Press release from the American Urological Association (AUA) discussing research presented at the 111th Annual Scientific Meeting, San Diego] Press Release
GenomeDx’s Decipher Platform Identifies Gene Expression Associated with Resistance to Chemotherapy Treatment in Bladder Cancer
GenomeDx Biosciences announced that its Decipher® platform was used to evaluate molecular subtypes associated with resistance to platinum-based neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer, supporting the potential use of a genomic signature to guide patient therapy. [Press release from GenomeDx Biosciences discussing research presented at the American Urological Association (AUA) 111th Annual Scientific Meeting, San Diego] Press Release
GTx Announces Presentation of Preclinical Data Demonstrating the Ability of SARDs to Degrade and Inhibit the Androgen Receptor
GTx, Inc. announced the first public presentation of preclinical data from the company’s selective androgen receptor (AR) degrader (SARD) program. The results demonstrate that the company’s highly potent SARDs selectively bind to the ligand binding domain and interact with the N-terminal domain of the androgen receptor and inhibit and degrade the AR at very low concentrations. [Press release from GTx, Inc. discussing research presented at the American Urological Association (AUA) 111th Annual Scientific Meeting, San Diego] Press Release
American Urological Association Honors Its 2016 Annual Award Winners
The American Urological Association (AUA) honored its 2016 AUA award recipients during its 111th Annual Meeting. These physician researchers, educators and organizations were honored for their contributions to the field of medicine, the specialty of urology and the AUA. [American Urological Association] Press Release
